TY - JOUR
T1 - Cardiovascular disease and chronic kidney disease
T2 - Insights and an update
AU - Best, Patricia J.M.
AU - Reddan, Donal N.
AU - Berger, Peter B.
AU - Szczech, Lynda A.
AU - McCullough, Peter A.
AU - Califf, Robert M.
PY - 2004/8
Y1 - 2004/8
N2 - Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.
AB - Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small under-powered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.
UR - http://www.scopus.com/inward/record.url?scp=4143068072&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2004.04.011
DO - 10.1016/j.ahj.2004.04.011
M3 - Article
C2 - 15308992
AN - SCOPUS:4143068072
SN - 0002-8703
VL - 148
SP - 230
EP - 242
JO - American Heart Journal
JF - American Heart Journal
IS - 2
ER -
